JP2929108B2 - Cosmetics and powder cosmetics - Google Patents
Cosmetics and powder cosmeticsInfo
- Publication number
- JP2929108B2 JP2929108B2 JP27232589A JP27232589A JP2929108B2 JP 2929108 B2 JP2929108 B2 JP 2929108B2 JP 27232589 A JP27232589 A JP 27232589A JP 27232589 A JP27232589 A JP 27232589A JP 2929108 B2 JP2929108 B2 JP 2929108B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- agent
- cosmetic
- powder
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002537 cosmetic Substances 0.000 title claims description 39
- 239000000843 powder Substances 0.000 title claims description 24
- 239000003205 fragrance Substances 0.000 claims description 13
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 12
- 239000006097 ultraviolet radiation absorber Substances 0.000 claims description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000003899 bactericide agent Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000007788 roughening Methods 0.000 claims description 2
- 230000002421 anti-septic effect Effects 0.000 claims 2
- 239000003086 colorant Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000000203 mixture Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000006210 lotion Substances 0.000 description 16
- 210000003491 skin Anatomy 0.000 description 15
- 101710159621 Very-long-chain (3R)-3-hydroxyacyl-CoA dehydratase Proteins 0.000 description 14
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 14
- 238000005342 ion exchange Methods 0.000 description 12
- -1 cyclic oligosaccharide Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 229920000858 Cyclodextrin Polymers 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 3
- UWKAYLJWKGQEPM-UHFFFAOYSA-N 3,7-dimethylocta-1,6-dien-3-yl acetate Chemical compound CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000006096 absorbing agent Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 235000008524 evening primrose extract Nutrition 0.000 description 3
- 229940089020 evening primrose oil Drugs 0.000 description 3
- 239000010475 evening primrose oil Substances 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- NGYMOTOXXHCHOC-UHFFFAOYSA-N 3-methyl-5-(2,2,3-trimethylcyclopent-3-en-1-yl)pentan-2-ol Chemical compound CC(O)C(C)CCC1CC=C(C)C1(C)C NGYMOTOXXHCHOC-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 241000723346 Cinnamomum camphora Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 2
- 240000000912 Macadamia tetraphylla Species 0.000 description 2
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 2
- 239000012965 benzophenone Substances 0.000 description 2
- 229940007550 benzyl acetate Drugs 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 229930008380 camphor Natural products 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000035618 desquamation Effects 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 229930007744 linalool Natural products 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000010466 nut oil Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- VPKMGDRERYMTJX-CMDGGOBGSA-N 1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one Chemical compound CCC(=O)\C=C\C1C(C)=CCCC1(C)C VPKMGDRERYMTJX-CMDGGOBGSA-N 0.000 description 1
- RJURRZFUWSRXDY-UHFFFAOYSA-N 1-phenoxyethanol Chemical compound CC(O)OC1=CC=CC=C1.CC(O)OC1=CC=CC=C1 RJURRZFUWSRXDY-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- IHQAPALAJDLARL-UHFFFAOYSA-N 2,3-dihydroxypropyl 2,3-dimethoxy-3-phenylprop-2-enoate ethyl hexanoate Chemical compound CCCCCC(=O)OCC.OCC(O)COC(=O)C(OC)=C(OC)C1=CC=CC=C1 IHQAPALAJDLARL-UHFFFAOYSA-N 0.000 description 1
- JPWUIQIFCDAWQX-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(O)CO JPWUIQIFCDAWQX-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- FACFHHMQICTXFZ-UHFFFAOYSA-N 2-(2-phenylimidazo[1,2-a]pyridin-3-yl)ethanamine Chemical compound N1=C2C=CC=CN2C(CCN)=C1C1=CC=CC=C1 FACFHHMQICTXFZ-UHFFFAOYSA-N 0.000 description 1
- DJCYDDALXPHSHR-UHFFFAOYSA-N 2-(2-propoxyethoxy)ethanol Chemical compound CCCOCCOCCO DJCYDDALXPHSHR-UHFFFAOYSA-N 0.000 description 1
- AHDXKQAZDADIGD-UHFFFAOYSA-N 2-propan-2-ylhexadecanoic acid Chemical compound CCCCCCCCCCCCCCC(C(C)C)C(O)=O AHDXKQAZDADIGD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-M 4-aminobenzoate Chemical compound NC1=CC=C(C([O-])=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZXGMMHMAGOAFGQ-UHFFFAOYSA-N 6-methyl-3-oxa-13-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(17),2(7),8-trien-4-one Chemical compound C1CCN2CCCC3=C2C1=C1OC(=O)CC(C)C1=C3 ZXGMMHMAGOAFGQ-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019300 CLIPPERS Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- XPDXVDYUQZHFPV-UHFFFAOYSA-N Dansyl Chloride Chemical compound C1=CC=C2C(N(C)C)=CC=CC2=C1S(Cl)(=O)=O XPDXVDYUQZHFPV-UHFFFAOYSA-N 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 235000003956 Luffa Nutrition 0.000 description 1
- 244000050983 Luffa operculata Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical compound CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- GUUHFMWKWLOQMM-UHFFFAOYSA-N alpha-n-hexylcinnamic aldehyde Natural products CCCCCCC(C=O)=CC1=CC=CC=C1 GUUHFMWKWLOQMM-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- YETXGSGCWODRAA-UHFFFAOYSA-N isopropyl palmitic acid Natural products CC(C)CCCCCCCCCCCCCCCC(O)=O YETXGSGCWODRAA-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940067137 musk ketone Drugs 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【発明の詳細な説明】 (産業上の利用分野) 本発明は、水難溶性成分をヒドロキシアルキル化シク
ロデキストリン(以下、HACDと略する)で包接した包接
物を配合した化粧料および粉末化粧料に関する。さらに
詳しくは、HACDで包接した包接物を配合することによっ
て、製品特性、使用性、安定性が改善され、しかも肌荒
れ防止に対して有効に作用する化粧料および粉末化粧料
に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial application field) The present invention relates to a cosmetic and a powder cosmetic containing a clathrate in which a poorly water-soluble component is included with a hydroxyalkylated cyclodextrin (hereinafter abbreviated as HACD). About charges. More specifically, the present invention relates to cosmetics and powder cosmetics which are improved in product properties, usability, and stability by blending inclusions included in HACD, and which effectively act to prevent rough skin.
(従来の技術) 従来から、よく知られている化粧水、ローション、美
容液などの化粧料は、水、アルコール等の主成分以外に
油脂類、生理活性物質、紫外線吸収剤、消炎剤、香料な
どの各種の水難溶性成分が使用性、有用性などを高める
目的で少量の界面活性剤を利用して配合されている。(Conventional technology) Conventionally well-known cosmetics such as lotions, lotions, and serums include oils and fats, physiologically active substances, ultraviolet absorbers, anti-inflammatory agents, and fragrances in addition to main components such as water and alcohol. And various water-insoluble components are incorporated using a small amount of a surfactant for the purpose of enhancing usability, usefulness, and the like.
また、日焼け後などの皮膚の改善に用いられる粉末化
粧料は、水溶解性粉末基材に皮膚賦活剤、薬剤などの水
難溶性成分が混合されている。Powder cosmetics used for improving skin after sunburn, etc., have a water-soluble powder base mixed with poorly water-soluble components such as skin activators and drugs.
(発明が解決しようとする課題) 化粧料において、上記水難溶性成分を配合する際に量
的な制限が生じることは、よく知られていることであ
る。そのために例えば、水難溶性成分を多量にかつ均一
状態に可溶化させるためには界面活性剤、エタノールま
たはポリオールなどを大量に配合しなければならない
が、これらを大量に配合すると皮膚を刺激するという問
題が生じた。また、水難溶性成分が均一に溶解しないこ
とにより、化粧料が白濁したり、透明感がなくなったり
して商品価値を低下させるという問題もあった。さらに
また、配合した水難溶性成分が化粧料中の他の成分に働
きかけ、それら他の成分の劣化、分解を早めてしまうと
いう問題も生じていた。(Problems to be Solved by the Invention) It is well known that in cosmetics, a quantitative limitation is caused when the poorly water-soluble component is blended. Therefore, for example, in order to solubilize a poorly water-soluble component in a large amount and in a uniform state, a large amount of a surfactant, ethanol, or a polyol must be blended. Occurred. In addition, since the poorly water-soluble component is not uniformly dissolved, there is also a problem that the cosmetic becomes cloudy or loses transparency, thereby lowering the commercial value. Furthermore, there has been a problem that the poorly water-soluble component added acts on other components in the cosmetic to accelerate deterioration and decomposition of the other components.
これらの問題点を解決するためには、特開昭61−2275
17号などに記載されているようにシクロデキストリンポ
リマーの包接作用を利用して上記成分を配合する技術が
知られている。しかしこの方法ではシクロデキストリン
ポリマー自体が一定の品質を得にくいこと、また該ポリ
マーはやや粘性を有し水に解けにくいことのため満足の
いく結果を得ることができなかった。To solve these problems, Japanese Patent Application Laid-Open No. 61-2275
As described in No. 17, etc., a technique of blending the above-mentioned components by utilizing the inclusion function of a cyclodextrin polymer is known. However, in this method, satisfactory results could not be obtained because the cyclodextrin polymer itself was difficult to obtain a certain quality and the polymer was slightly viscous and hardly soluble in water.
また、粉末形状で市販され使用時に水を加えて使用す
るタイムの粉末化粧料にあっては、少量しか水を使用し
ないで掌などで可溶化させるため、水難溶性成分が均一
には溶解されず、そのため使用時にザラツイタ感触が残
るとともに、薬効を十分発揮できないという問題があっ
た。これらの解決手段として界面活性剤の量を増加させ
たり、シクロデキストリンポリマーの包接作用を利用し
たりする技術もみられたが、上記と同様の理由により好
ましい結果を得ることができなかった。In addition, in the case of powdered cosmetics that are commercially available in powder form and use water when used at the time of use, since only a small amount of water is used and solubilized in the palm or the like, poorly water-soluble components are not uniformly dissolved. Therefore, there is a problem that the texture of the material remains when used, and the medicinal effect cannot be sufficiently exhibited. Techniques for increasing the amount of the surfactant or utilizing the inclusion function of the cyclodextrin polymer have been found as solutions to these problems, but a favorable result could not be obtained for the same reason as described above.
また従来のシクロデキストリンポリマーでは肌荒れ防
止に対して十分な効果をあげられるものはなかった。し
かし最近では美肌に重点をおいた素肌づくりの傾向があ
り、化粧料の製品としての特性等の他に、肌荒れ防止に
対して有効な化粧料が強く望まれるようになってきた。Further, none of the conventional cyclodextrin polymers has a sufficient effect for preventing rough skin. However, recently there has been a tendency to create bare skin with an emphasis on beautiful skin, and in addition to the properties of cosmetics as products, effective cosmetics that are effective in preventing rough skin have been strongly desired.
本発明の目的は、このような現状に鑑みてなされたも
ので、可溶化しやすいHACDの包接作用を利用することに
より界面活性剤、エタノールまたはポリオールなどの可
溶化剤を大量に使用することなく、安全性が高く、溶解
性、使用性、安定性に優れ、しかも肌荒れ防止に有効に
作用する化粧料および粉末化粧料を提供するものであ
る。The object of the present invention has been made in view of such a situation, and uses a large amount of a solubilizing agent such as a surfactant, ethanol or a polyol by utilizing the inclusion effect of HACD which is easily solubilized. The present invention provides a cosmetic and a powder cosmetic which are highly safe, have excellent solubility, usability, and stability, and effectively act to prevent rough skin.
(課題を解決するための手段) すなわち、本発明の上記目的は、 1)水難溶性成分をヒドロキシアルキル化シクロデキス
トリンで包接した包接物を配合したことを特徴とする化
粧料又は 2)水難溶性成分をヒドロキシアルキル化シクロデキス
トリンで包接した包接物を配合したことを特徴とする粉
末化粧料によって達成される。(Means for Solving the Problems) That is, the above objects of the present invention are as follows: 1) a cosmetic comprising a clathrate in which a poorly water-soluble component is included with a hydroxyalkylated cyclodextrin; This is achieved by a powder cosmetic comprising a clathrate in which a soluble component is clathrated with a hydroxyalkylated cyclodextrin.
以下に、本発明について詳述する。 Hereinafter, the present invention will be described in detail.
本発明に使用されるHACDは、従来から環状のオリゴ糖
としてよく知られているシクロデキストリンの水酸基に
ヒドロキシアルキル基を導入したものである。HACD used in the present invention is obtained by introducing a hydroxyalkyl group into a hydroxyl group of cyclodextrin, which is well known as a cyclic oligosaccharide.
ヒドロキシアルキル基としては、主にヒドロキシメチ
ル、ヒドロキシエチル、ヒドロキシプロピル、ヒドロキ
シブチルなどの置換基が使用され、これら置換反応の結
果、ヒドロキシメチルシクロデキストリン、ヒドロキシ
エチルシクロデキストリン、ヒドロキシプロピルシクロ
デキストリン、ヒドロキシブチルシクロデキストリンな
どのHACDを得ることができる。As the hydroxyalkyl group, substituents such as hydroxymethyl, hydroxyethyl, hydroxypropyl, and hydroxybutyl are mainly used. As a result of these substitution reactions, hydroxymethylcyclodextrin, hydroxyethylcyclodextrin, hydroxypropylcyclodextrin, hydroxybutyl HACD such as cyclodextrin can be obtained.
シクロデキストリン(以下、CDと略する。)は、グル
コースの数の違いによってα、β、γの構造をもつCD
(以下、α−CD、β−CD、γ−CDと略する。)が知られ
ているが、本発明はこれらのCDの1種または2種以上を
ヒドロキシアルキル化して使用できる。α、β、γのCD
を同時に含有する澱粉分解物も使用できる。Cyclodextrin (hereinafter abbreviated as CD) is a CD having α, β, and γ structures depending on the number of glucoses.
(Hereinafter abbreviated as α-CD, β-CD, and γ-CD), but in the present invention, one or more of these CDs can be hydroxyalkylated and used. α, β, γ CD
Can also be used.
これらHACDは、表1に示したように従来のCDに比べ、
水などの親水性溶媒に対する溶解性が非常に優れたもの
であり、本発明はこの性質とHACDの包接作用を利用して
水難溶性成分を化粧料中に任意量配合するものである。These HACDs are, as shown in Table 1, compared to conventional CDs.
The solubility in a hydrophilic solvent such as water is extremely excellent, and the present invention utilizes this property and the inclusion effect of HACD to incorporate an optional amount of a poorly water-soluble component into a cosmetic.
価格、製造容易性、使用性及び水溶解性を考慮した場
合、これらHACDのうち、ヒドロキシエチル化CDまたはヒ
ドロキシプロピル化CDが好ましく、さらに好ましくはヒ
ドロキシエチル化β−CD、ヒドロキシプロピル化β−CD
が好ましいが、これに限定されるものではない。 In consideration of price, ease of production, usability and water solubility, among these HACDs, hydroxyethylated CD or hydroxypropylated CD is preferred, and hydroxyethylated β-CD and hydroxypropylated β-CD are more preferred.
Is preferred, but is not limited thereto.
また、ヒドロキシエチル化CDまたはヒドロキシプロピ
ル化CDは製造状態においてはα、β、γが混じりあった
混合物となっているが、混合物のままでもα、β、γの
ヒドロキシプロピル化CDを単離したものでも使用するこ
とができる。In addition, although hydroxyethylated CD or hydroxypropylated CD is a mixture of α, β, and γ in the production state, α, β, and γ-hydroxypropylated CD were isolated as a mixture. Anything can be used.
HACDの製造方法としては、従来からいくつかの方法が
知られているが、以下に一例を示す。As a method for producing HACD, several methods have been conventionally known, and an example is shown below.
β−CD(日本食品化工製、商標名:セルデックスN)
100gを20%NaOH水溶液150mlに溶解し、30℃に保持しつ
つ酸化プロピレン50mlを徐々に滴下し、20時間攪拌し反
応を続ける。反応終了後、塩酸でpH6.0に中和し、透析
膜チューブ中に入れ、流水下24時間脱塩を行なった。そ
の後凍結乾燥機で乾燥を行なって、ヒドロキシプロピル
化β−シクロデキストリン約90gが得られた。このヒド
ロキシプロピル化β−シクロデキストリンのCD当たりの
置換度は5.1であった。β-CD (Nippon Shokuhin Kako, brand name: Celldex N)
100 g is dissolved in 150 ml of a 20% aqueous solution of NaOH, and while maintaining the temperature at 30 ° C., 50 ml of propylene oxide is gradually added dropwise, followed by stirring for 20 hours to continue the reaction. After completion of the reaction, the mixture was neutralized to pH 6.0 with hydrochloric acid, placed in a dialysis membrane tube, and desalted under running water for 24 hours. Thereafter, drying was carried out with a freeze dryer to obtain about 90 g of hydroxypropylated β-cyclodextrin. The substitution degree per CD of the hydroxypropylated β-cyclodextrin was 5.1.
本発明に用いられる水難溶製成分とは、実質的に水に
全く溶解しないか、あるいは僅かに溶解する化粧料成分
を意味する。その具体例としては、例えば、マカデミア
ナッツ油、月見草油、オリーブ油、ミンク油、ホホバ
油、ラノリン、スクワレン等の天然動植物油脂類、流動
パラフィン、スクワラン等の炭化水素類、パラフィンワ
ックス鯨ロウ、密ロウ、キャンデリラワックス、カルナ
ウバロウ等のワックス類、セタノール、イソセタノー
ル、ステアリルアルコール、イソステアリルアルコール
等の高級アルコール類、ミリスチン酸、パルミチン酸、
ステアリン酸、ベヘニン酸、イソステアリン酸、オレイ
ン酸、リノレン酸、リノール酸、リノレイン酸、オキシ
酸等の高級脂肪酸類、イソプロピルミリスチン酸、イソ
プロピルパルミチン酸、イソプロピルイソステアリン
酸、2エチルヘキサン酸グリセリール等のエステル類、
ジエチレングリコールモノプロピルエーテル、ポリオキ
シエチレンポリオキシプロピレンペンタエリスリトール
エーテル、ポリオキシプロピレンブチルエーテル、リノ
ール酸エチル等の極性オイル、その他シリコーン油等を
加えることもできる。The poorly water-soluble component used in the present invention means a cosmetic component which is practically completely insoluble or slightly soluble in water. Specific examples thereof include, for example, macadamia nut oil, evening primrose oil, olive oil, mink oil, jojoba oil, natural animal and vegetable oils and fats such as lanolin, squalene, liquid paraffin, hydrocarbons such as squalane, paraffin wax whale wax, beeswax, Waxes such as candelilla wax, carnauba wax, higher alcohols such as cetanol, isocetanol, stearyl alcohol, and isostearyl alcohol, myristic acid, palmitic acid,
Higher fatty acids such as stearic acid, behenic acid, isostearic acid, oleic acid, linolenic acid, linoleic acid, linoleic acid, and oxyacid, esters such as isopropyl myristate, isopropyl palmitic acid, isopropyl isostearic acid, and glyceryl 2-ethylhexanoate ,
Polar oils such as diethylene glycol monopropyl ether, polyoxyethylene polyoxypropylene pentaerythritol ether, polyoxypropylene butyl ether, ethyl linoleate, and other silicone oils can also be added.
さらにビタミンA、ビタミンD、ビタミンE、酢酸ト
コフェロール、アスコルビン酸エステル等のビタミン類
及びγ−オリザノール、葉酸などのビタミン類及びビタ
ミン様作用物質類、安息香酸、エストラジオール、吉草
酸エストラジオール、エチニルエストラジオール、プロ
スタグランジン、プロピオン酸テストステロン等のホル
モン類、ベンゾフェノン、4−t−ブチル−4′メトキ
シ−ジベンゾイルメタン、ジメトキシケイ皮酸エチルヘ
キサン酸グリセリル、p−アミノ安息香酸エステル、パ
ラメトキシケイ皮酸オクチル、サリチル酸フェニル等の
紫外線吸収剤類、L−メントール、カンファー等の消炎
剤、エチルパラベン、プロピルパラベン、ブチルパラベ
ン等の防腐剤、グリチルレチン酸、トリクロサン、ジブ
チルヒドロキシトルエン等の殺菌剤が含まれる。また、
オイルレッド、ナフトールイエロー、タートラジン、パ
プリカ等の油溶性色素類、さらに香料成分としてリナロ
ール、リナリールアセテート、リモネン、シトラール、
メチルイオノン、ベンジルアセテート、メチルデヒドロ
ジャスモネート、フェニルエチルアルコール、ムスクケ
トン、サンダロール、α−ヘキシルシンナミックアルデ
ヒド、TEC、シトロネロール等の単品香料及びこれらを
混合した調合香料、生薬類を挙げることができる。Furthermore, vitamins such as vitamin A, vitamin D, vitamin E, tocopherol acetate, ascorbic acid ester and vitamins such as γ-oryzanol and folic acid and vitamin-like active substances, benzoic acid, estradiol, estradiol valerate, ethinylestradiol, prosta Glandins, hormones such as testosterone propionate, benzophenone, 4-tert-butyl-4'methoxy-dibenzoylmethane, glyceryl dimethoxycinnamate ethylhexanoate, p-aminobenzoate, octyl paramethoxycinnamate, UV absorbers such as phenyl salicylate, anti-inflammatory agents such as L-menthol, camphor, preservatives such as ethylparaben, propylparaben, butylparaben, glycyrrhetinic acid, triclosan, dibutylhydroxytoluene Fungicides such as emissions are included. Also,
Oil-soluble pigments such as oil red, naphthol yellow, tartrazine, paprika, and further, as a fragrance component, linalool, linalool acetate, limonene, citral,
Individual perfumes such as methylionone, benzyl acetate, methyl dehydrojasmonate, phenylethyl alcohol, musk ketone, sandalore, α-hexylcinnamic aldehyde, TEC, citronellol, and the like, and mixed perfumes and crude drugs can be mentioned.
これらの性状は液状ないし結晶状いずれであってもよ
く、単独もしくは2種以上の混合物の形で用いられる。These properties may be liquid or crystalline, and are used alone or in the form of a mixture of two or more.
このような水難溶性成分とHACDを用いて包接物を製造
するには、以下のような周知の方法が用いられる。The following well-known method is used to produce an inclusion using such a poorly water-soluble component and HACD.
HACD20〜60重量%の水溶液に、所要の上記成分をHACD
1重量部に対して、0.01〜0.15重量部添加混合し、20〜5
0℃で攪拌混合を行なう。攪拌条件は50〜3000rpmで、包
接反応時間は2〜8時間である。HACD 20% to 60% by weight aqueous solution
For 1 part by weight, add 0.01 to 0.15 parts by weight and mix
Stir and mix at 0 ° C. The stirring conditions are 50 to 3000 rpm, and the inclusion reaction time is 2 to 8 hours.
このようにして得られた包接物は、水溶液中で可溶化
または乳化していて、このまま使用することができる
が、この水溶液を凍結乾燥やスプレードライ等の処理を
行ない微粉末化して使用することもできる。本願第一の
発明を化粧料においては、反応液の状態または微粉末化
した状態のいずれでも配合することが可能である。The clathrate thus obtained is solubilized or emulsified in an aqueous solution and can be used as it is. However, this aqueous solution is subjected to treatment such as freeze-drying or spray-drying to be used as fine powder. You can also. In the cosmetics, the first invention of the present application can be blended in any of a reaction liquid state and a finely powdered state.
上記包接物の本願第一の発明の化粧料への配合量は、
包接した水難溶性成分の種類と化粧料の種類によって左
右されるが、一般的に微粉末化した状態で好ましくは全
化粧料中の25重量%、更に好ましくは15重量%までであ
る。これ以上に配合することも技術的に十分可能である
が使用時にべたつくという欠点が生じてくる。The compounding amount of the clathrate in the cosmetic of the first invention of the present application is
Although it depends on the kind of the hardly water-soluble component included and the kind of the cosmetic, it is generally preferably 25% by weight, more preferably up to 15% by weight of the total cosmetic in a finely powdered state. It is technically possible to mix more than this, but there is the disadvantage that it sticks during use.
本願第一の発明の化粧料は、前記の成分のほかに、そ
の商品特徴に応じて、他の化粧料成分、例えば、ヒアル
ロン酸などの保湿剤、ビタミンCなどの水溶性薬剤、粘
度調整剤、pH調整剤、防腐剤、殺菌剤、酸化防止剤、香
料、色素等を配合することができる。The cosmetic of the first invention of the present application is, in addition to the above-mentioned components, other cosmetic components, for example, a humectant such as hyaluronic acid, a water-soluble drug such as vitamin C, a viscosity modifier, depending on the characteristics of the product. , A pH adjuster, a preservative, a bactericide, an antioxidant, a fragrance, a pigment, and the like.
本願第2の発明の粉末化粧料には、本願第1の発明の
化粧料で用いたものと同一の包接物が用いられる。ただ
し、使用直前まで乾燥した製品形態を維持するため、HA
CDの包接物も微粉末化した乾燥状態で他の水溶性基材成
分中に加えられていることが好ましい。HACDの包接物の
粉末化粧料中への配合料は、微粉末化した状態で好まし
くは全粉末化粧料中の50重量%、更に好ましくは40重量
%までである。50重量%以上でも溶解性には問題がない
が、使用時にべたつくという問題が生じる。The same clathrate used in the cosmetic of the first aspect of the present invention is used for the powder cosmetic of the second aspect of the present invention. However, in order to maintain a dry product form until just before use, HA
It is preferable that the clathrate of CD is also added in a finely powdered dry state to the other water-soluble base component. The compounding amount of the HACD clathrate in the powder cosmetic is preferably 50% by weight, more preferably up to 40% by weight of the total powder cosmetic in a finely powdered state. Although there is no problem in solubility at 50% by weight or more, there is a problem that it is sticky at the time of use.
本願第2の発明の粉末化粧料には、HACDの包接物以外
にD−マンニット、乳糖などの可溶性粉末基材、さらに
商品特徴に応じて、他の化粧料成分、例えば、ヒアルロ
ン酸などの保湿剤、ビタミンCなどの水溶性薬剤、粘度
調整剤、pH調整剤、防腐剤、殺菌剤、酸化防止剤、香
料、色素等を配合することができる。The powder cosmetic of the second invention of the present application includes, in addition to the inclusion compound of HACD, a soluble powder base such as D-mannitol and lactose, and other cosmetic ingredients such as hyaluronic acid depending on the characteristics of the product. Humectants, water-soluble drugs such as vitamin C, viscosity modifiers, pH regulators, preservatives, bactericides, antioxidants, fragrances, pigments, and the like.
(発明の効果) 本発明によって、従来から配合が限定されていた水難
溶性成分を界面活性剤やアルコールの力をかりることな
く任意量配合でき、透明性、安定性、安全性、使用性に
優れ、しかも肌荒れ防止に対して有効に作用する化粧料
及び粉末化粧料を得ることができた。また、本発明にお
いては、水難溶性物質がHACDによって包接されているの
で、化粧料中又は粉末化粧料中の他の成分に影響を与え
ることなく、他の成分が長期間安定するという効果を有
していた。(Effects of the Invention) According to the present invention, a sparingly water-soluble component, which has been conventionally limited in blending, can be blended in any amount without using the power of a surfactant or alcohol, and is excellent in transparency, stability, safety and usability. In addition, it was possible to obtain a cosmetic and a powder cosmetic which effectively act to prevent rough skin. Further, in the present invention, since the poorly water-soluble substance is included by the HACD, the other components in the cosmetic or the powdered cosmetic are not affected and the effect that the other components are stable for a long time is obtained. Had.
更に、本願第2の発明においては、使用時に少量の水
で完全に溶解しうるという効果も有していた。Further, the second invention of the present application also has an effect that it can be completely dissolved with a small amount of water at the time of use.
(実施例) 次に本発明を実施例によりさらに詳細に説明する。配
合量は重量%で示した。(Examples) Next, the present invention will be described in more detail with reference to examples. The compounding amount was shown by weight%.
実施例1 保湿化粧水 1剤 ヒドロキシプロピル化CD混合物 2.5 マカデミアナッツオイル 0.5 ビタミンEアセテート 0.05 イオン交換水 40 2剤 イオン交換水 39.729 ソルビトール 5 1,3ブチレングリコール 12 乳酸 0.02 乳酸ナトリウム 0.1 グリチルリン酸モノアンモニウム 0.1 色素 0.001 (製法) のヒドロキシプロピル化CD混合物2.5gをイオン交換
水40gに溶解し、さらに、を加えて攪拌してヒドロ
キシプロピル化CD混合物の包接物が含まれる1剤を調製
した。Example 1 Moisturizing lotion 1 agent Hydroxypropylated CD mixture 2.5 Macadamia nut oil 0.5 Vitamin E acetate 0.05 Ion exchange water 40 2 agents Ion exchange water 39.729 Sorbitol 5 1,3 Butylene glycol 12 Lactic acid 0.02 Sodium lactate 0.1 Monoammonium glycyllate 0.1 Dye 2.5 g of the hydroxypropylated CD mixture of 0.001 (manufacturing method) was dissolved in 40 g of ion-exchanged water, and further added and stirred to prepare one agent containing the inclusion product of the hydroxypropylated CD mixture.
次に2剤に上記1剤を加えて油分、薬剤が安定に配合
された保湿化粧水を得た。Next, the above-mentioned one agent was added to the two agents to obtain a moisturizing lotion in which the oil component and the agent were stably blended.
上記組成物からヒドロキシプロピル化CD混合物を除い
たものは、油分と薬剤が分離して安定性の良い化粧水と
はならなかった。When the hydroxypropylated CD mixture was removed from the above composition, the oil and the drug were separated, and the stable lotion was not obtained.
実施例2 全身用ローション 2剤 イオン交換水 49.8699 PEG400 1.0 ヒノキチオール 0.01 ヘチマ抽出液 1.0 アイリス抽出液 1.0 変性95%エタノール 40.0 香料 0.05 色素 0.001 (製法) をイオン交換水に溶解し、さらに、、の紫外
線吸収剤を加えて攪拌し、ヒドロキシプロピル化β−CD
の包接物が含まれる1剤を調製した。Example 2 Lotion for whole body 2 agents Ion-exchanged water 49.8699 PEG400 1.0 Hinokitiol 0.01 Luffa extract 1.0 Iris extract 1.0 Denatured 95% ethanol 40.0 Fragrance 0.05 Dye 0.001 (Preparation method) Dissolve in ion-exchanged water, add a UV absorber and stir , Hydroxypropylated β-CD
Was prepared containing the clathrate.
次に2剤に上記1剤を加えて紫外線吸収剤を安定に配
合した全身用ローションを得た。Next, the above-mentioned one agent was added to the two agents to obtain a whole body lotion stably containing an ultraviolet absorber.
上記組成物からヒドロキシプロピル化β−CDを除いた
ものは、紫外線吸収剤が分離して安定性のよいローショ
ンとはならなかった。When the hydroxypropylated β-CD was removed from the above composition, the ultraviolet absorber was separated and the composition did not become a stable lotion.
実施例3 エッセンス 1剤 ヒドロキシプロピル化α−CD 10 月見草油 0.2 α−トコフェロール 0.05 イオン交換水 20 2剤 イオン交換水 59.26 ジプロピレングリコール 5 マルチトール 5 アスパラギン酸 0.04 L−アルギニン 0.1 ヘキサメタリン酸ナトリウム 0.05 カルボキシビニルポリマー 0.2 香料 0.1 (製法) をイオン交換水に溶解し、さらにを加えて攪拌
しヒドロキシプロピル化α−CDの包接物を含む1剤を調
製した。Example 3 Essence 1 agent Hydroxypropylated α-CD 10 evening primrose oil 0.2 α-tocopherol 0.05 ion exchange water 20 2 agents ion exchange water 59.26 dipropylene glycol 5 maltitol 5 aspartic acid 0.04 L-arginine 0.1 sodium hexametaphosphate 0.05 carboxyvinyl Polymer 0.2 perfume 0.1 (production method) was dissolved in ion-exchanged water, further added, and the mixture was stirred to prepare an agent containing a clathrate of hydroxypropylated α-CD.
次に2剤に上記1剤を加えて油分の酸化防止剤を安定
に配合したエッセンスを得た。Next, the above-mentioned one agent was added to the two agents to obtain an essence in which an oil antioxidant was stably mixed.
上記組成物からヒドロキシプロピル化α−CDを除いた
ものは油分と酸化防止剤が分離して均一性がなくなり安
定性に劣るものであった。When the hydroxypropylated α-CD was removed from the above composition, the oil content and the antioxidant were separated, resulting in poor uniformity and poor stability.
実施例4 化粧水 2剤 イオン交換水 82.0948 グリセリン 1.0 1,3ブチレングリコール 2.0 乳酸 0.005 乳酸ナトリウム 0.2 グリチルリチン酸モノアンモニウム塩 0.05 アロエ抽出液 0.5 変性95%エタノール 10.0 色素 0.0002 (製法) をイオン交換水に溶解し、さらにを加え攪拌し
ヒドロキシプロピル化γ−CDの包接物を含む1剤を調製
した。Example 4 Lotion 2 agents Ion exchange water 82.0948 Glycerin 1.0 1,3 Butylene glycol 2.0 Lactic acid 0.005 Sodium lactate 0.2 Monoammonium glycyrrhizinate 0.05 Aloe extract 0.5 Denatured 95% ethanol 10.0 Pigment 0.0002 Dissolve 0.0002 (production method) in ion exchange water, and add The mixture was stirred to prepare an agent containing the inclusion compound of hydroxypropylated γ-CD.
次に2剤に上記1剤を加えて紫外線吸収剤と香料を安
定に配合した化粧水を得た。Next, the above-mentioned one agent was added to the two agents to obtain a lotion in which an ultraviolet absorber and a fragrance were stably blended.
実施例5 収斂化粧水 2剤 イオン交換水 57.57 ジプロピレングリコール 2.0 クエン酸 0.03 クエン酸ソーダ 0.05 スルフォ石炭酸亜鉛 0.2 変性95%エタノール 15.0 メチルパラベン 0.1 (製法) をイオン交換水に溶解し、さらにを加え攪拌
しヒドロキシエチル化β−CDの包接物が含まれる1剤を
調製した。Example 5 Astringent lotion Two agents Ion-exchanged water 57.57 Dipropylene glycol 2.0 Citric acid 0.03 Sodium citrate 0.05 Sulfocalcium carbonate 0.2 Denatured 95% ethanol 15.0 Methylparaben 0.1 (Preparation method) Dissolve in ion-exchanged water, add and stir, add hydroxyethylated β-CD Was prepared containing the clathrate.
次に2剤に上記1剤を加えて紫外線吸収剤と香料、色
素を安定に配合した収斂化粧水を得た。Next, the above-mentioned one agent was added to the two agents to obtain an astringent lotion stably blending an ultraviolet absorber, a fragrance and a pigment.
実施例6 ノンアルコール系化粧水 1剤 ヒドロキシメチル化β−CD 10 メントール 3 香料(ローズオキシサイド) 0.01 イオン交換水 20 2剤 イオン交換水 56.46 ジプロピレングリコール 10 クエン酸 0.03 クエン酸ソーダ 0.05 メチルパラベン 0.1 フェノキシエタノール 0.3 色素 0.05 (製法) をイオン交換水に溶解し、さらに、を加えて攪
拌してヒドロキシメチル化β−CDの包接物が含まれる1
剤を調製した。Example 6 Non-alcohol lotion 1 agent Hydroxymethylated β-CD 10 Menthol 3 Fragrance (rose oxyside) 0.01 Ion exchange water 20 2 agents Ion exchange water 56.46 Dipropylene glycol 10 Citric acid 0.03 Sodium citrate 0.05 Methyl paraben 0.1 Phenoxyethanol 0.3 Dye 0.05 (Preparation method) is dissolved in ion-exchanged water, and further added and stirred to contain the inclusion compound of hydroxymethylated β-CD.
An agent was prepared.
次に2剤に上記1剤を加えて消炎剤、香料を安定に配
合したノンアルコール系化粧水を得た。Next, the above-mentioned one agent was added to the two agents to obtain a non-alcohol lotion in which an anti-inflammatory agent and a fragrance were stably blended.
実施例7 粉末入り化粧水 1剤 ヒドロキシブチル化β−CD 6.0 l−メントール 0.3 カンファー 0.5 香料(ベンジルアセテート) 0.15 イオン交換水 15 2剤 イオン交換水 69.65 グリセリン 1.0 アスパラギン 0.05 変性95%エタノール 5.0 亜鉛 1.5 カオリン 0.5 メチルパラベン 0.05 粘土鉱物 0.3 (製法) をイオン交換水に溶解し、さらにを加えて攪
拌してヒドロキシブチル化β−CDの包接物が含まれる1
剤を調製した。Example 7 Powdered lotion 1 agent Hydroxybutylated β-CD 6.0 l-menthol 0.3 camphor 0.5 Fragrance (benzyl acetate) 0.15 ion exchange water 15 2 agents ion exchange water 69.65 glycerin 1.0 asparagine 0.05 denatured 95% ethanol 5.0 zinc 1.5 kaolin 0.5 Methyl paraben 0.05 Clay mineral 0.3 (Preparation method) is dissolved in ion-exchanged water, added and stirred, and the inclusion of hydroxybutylated β-CD is included.
An agent was prepared.
次に2剤に上記1剤を加えて消炎剤、香料を安定に配
合した粉末入り化粧水を得た。Next, the above-mentioned one agent was added to the two agents to obtain a powdered lotion in which an anti-inflammatory agent and a fragrance were stably blended.
実施例8 ホワイトパウダー (製法) をイオン交換水に溶解し、さらにを加え攪拌
してヒドロキシプロピル化CD混合物の包接物を含む1剤
を調製した。この1剤を凍結乾燥により粉末状とした。Example 8 White powder (Preparation method) was dissolved in ion-exchanged water, and further added, followed by stirring to prepare an agent containing a clathrate of a hydroxypropylated CD mixture. This one agent was lyophilized to powder.
次に2剤に上記1剤の粉末を加えて紫外線吸収剤を安
定に配合したホワイトパウダーを得た。Next, the powder of the one agent was added to the two agents to obtain a white powder in which an ultraviolet absorber was stably compounded.
実施例9 エッセンスパウダー 1剤 ヒドロキシプロピル化CD混合物 8 月見草油 0.1 α−トコフェロール 0.05 ヒアルロン酸 0.001 イオン交換水 12 2剤 乳糖 79.849 (製法) をイオン交換水に溶解し、さらにを加えて撹
拌して、ヒドロキシプロピル化CD混合物の包接物を含む
1剤を調製した。この1剤をスプレードライにより粉末
状とした。Example 9 Essence powder 1 agent Hydroxypropylated CD mixture 8 Evening primrose oil 0.1 α-tocopherol 0.05 Hyaluronic acid 0.001 Ion exchange water 12 2 agents Lactose 79.849 (production method) was dissolved in ion exchange water, and further added and stirred. One preparation was prepared containing the inclusion of the hydroxypropylated CD mixture. This one agent was powdered by spray drying.
次に2剤に上記1剤の粉末を加えて油分、酸化防止
剤、保湿剤を安定に配合したエッセンスパウダーを得
た。Next, the powder of the one agent was added to the two agents to obtain an essence powder in which an oil, an antioxidant, and a humectant were stably blended.
実施例10 サンケアパウダー 1剤 ヒドロキシプロピル化α−CD 4.0 ベンゾフェノン 0.05 イオン交換水 6 (製法) ヒドロキシプロピル化α−CDをイオン交換水に溶かし
を加え攪拌し、紫外線吸収剤複合物溶液とし乾燥させ
て1剤を調製した。Example 10 Sun care powder 1 agent Hydroxypropylated α-CD 4.0 Benzophenone 0.05 Ion-exchanged water 6 (Preparation method) Hydroxypropylated α-CD was dissolved in ion-exchanged water, and the mixture was stirred and made into an ultraviolet absorbent composite solution, followed by drying to prepare one preparation.
次にヒドロキシプロピル化β−CDをイオン交換水に溶
かし、2剤のを加え攪拌し紫外線吸収剤複合物溶
液とし乾燥させて2剤を調製した。Next, the hydroxypropylated β-CD was dissolved in ion-exchanged water, the two agents were added, and the mixture was stirred to form an ultraviolet absorbent composite solution and dried to prepare two agents.
さらに、3剤のを混合して3剤とした。 Further, three agents were mixed to obtain three agents.
最後に前記3剤に1剤、2剤を加えて紫外線吸収剤を
安定に配合したサンケアパウダーを得た。Finally, a sun care powder was obtained by adding one agent and two agents to the three agents and stably blending the ultraviolet absorber.
実施例11 肌荒れに対する作用 試料として表2に示すような各種CD、またはCD誘導体
各5gをイオン交換水95gに溶解し、調合香料(リナロー
ル50%:リナリルアセテート20%:ラベンダーオイル10
%:サンダロール10%:クマリン10%)を0.01g加えて
攪拌し、CD中に調合香料を包接させたものを用いて肌荒
れに対する作用を調べた。Example 11 Effect on skin roughness 5 g of various CDs or CD derivatives as shown in Table 2 were dissolved in 95 g of ion-exchanged water as a sample, and a compounded flavor (linalool 50%: linalyl acetate 20%: lavender oil 10)
%: Sandalore 10%: coumarin 10%) was added and stirred, and the effect of roughening the skin was examined using a mixture prepared by enclosing the prepared flavor in CD.
体重700〜850gのHartley系雄モルモット3匹の背部の
毛をバリカンで刈り、更に脱毛処理を施した。脱毛後4
日目から脱毛処理を施した皮膚上の4ヵ所に3%アルキ
ルベンゼンスルホン酸ナトリウム(LAS)水溶液25mlを
1日1回連続塗布して肌合れを惹起した。更に同部位
に、LAS溶液塗布後、上記各試料50mlを1日1回塗布し
た。Hair of the back of three male Hartley guinea pigs weighing 700 to 850 g was clipped with a clipper and further depilated. 4 after hair removal
From the day, 25 ml of a 3% aqueous solution of sodium alkylbenzenesulfonate (LAS) was continuously applied once a day to four places on the hair that had been subjected to hair removal treatment once a day to induce skin contact. Further, after applying the LAS solution to the same site, 50 ml of each of the above samples was applied once a day.
LAS水溶液塗布開始から7日目の皮膚状態の変化を下
記の基準により紅斑及び落屑について評価し、これらの
平均値で示した。また紅斑及び落屑それぞれの平均値の
合計を肌荒れスコアとして表示した。結果を表2に示
す。The change in skin condition on the 7th day from the start of application of the LAS aqueous solution was evaluated for erythema and desquamation according to the following criteria, and the average value was shown. The sum of the average values of erythema and desquamation was displayed as a rough skin score. Table 2 shows the results.
肌合れスコアの数値の低い方が肌荒れ改善効果がある
が、表2から明らかなように、本発明におけるヒドロキ
シプロピル−β−CDは比較用試料に比べて皮膚の肌荒れ
に対して極めて有効に作用することがわかった。 The lower the value of the skin fit score is, the better the effect of improving skin roughness, but as is clear from Table 2, the hydroxypropyl-β-CD in the present invention is much more effective against skin roughness than the comparative sample. It turned out to work.
実施例12 角層ターンオーバーに対する作用 一方、試料溶液の角層のターンオーバーに対する作用
を調べるために、実施例11において、3%LAS水溶液を
塗布する前にダンシルクロライドを同部位に塗っておい
た以外は実施例11と同様にして各試料を塗布した。相対
蛍光値の経日変化から蛍光値が50%消失した時の日数を
算出した。結果を表3に示す。50%蛍光消失日数が短い
ほど角層のターンオーバーが加速され、肌荒れがすすん
でいることが示唆される。Example 12 Effect on turnover of stratum corneum On the other hand, in order to examine the effect of sample solution on turnover of stratum corneum, in Example 11, dansyl chloride was applied to the same site before applying a 3% LAS aqueous solution. Other than that, each sample was applied in the same manner as in Example 11. The number of days when the fluorescence value disappeared by 50% was calculated from the daily change of the relative fluorescence value. Table 3 shows the results. The shorter the 50% fluorescence disappearance days, the faster the horny layer turnover is accelerated, suggesting that the skin is rough.
表3から明らかなように、本発明におけるヒドロキシ
プロピル−β−CDは、比較用試料と比べて角層ターンオ
ーバーを抑制するのに極めて有効であることがわかっ
た。 As is clear from Table 3, the hydroxypropyl-β-CD in the present invention was found to be extremely effective in suppressing corneal turnover as compared with the comparative sample.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 上島 修 静岡県三島市加茂47―14 (56)参考文献 特開 昭54−70434(JP,A) 特開 昭63−192706(JP,A) 特開 昭61−227517(JP,A) 特表 昭61−500788(JP,A) (58)調査した分野(Int.Cl.6,DB名) A61K 7/00 - 7/50 ──────────────────────────────────────────────────続 き Continuation of front page (72) Inventor Osamu Uejima 47-14 Kamo, Mishima City, Shizuoka Prefecture (56) References JP-A-54-70434 (JP, A) JP-A-63-192706 (JP, A) JP-A-61-227517 (JP, A) JP-T-61-500788 (JP, A) (58) Fields investigated (Int. Cl. 6 , DB name) A61K 7/00-7/50
Claims (2)
剤、殺菌剤、油溶性色素剤及び香料からなる群から選択
された少なくとも1つの水難溶性成分をヒドロキシアル
キル化シクロデキストリンで包接した包接物を配合した
肌荒れ防止・改善性能に優れた化粧料であって、その包
接物含有料が全化粧料中の25重量%以下である肌荒れ防
止・改善性能に優れた化粧料(1) at least one poorly water-soluble component selected from the group consisting of a polar oil, an ultraviolet absorber, an anti-inflammatory agent, an antiseptic, a bactericide, an oil-soluble coloring agent and a fragrance is included in a hydroxyalkylated cyclodextrin. Cosmetic excellent in prevention and improvement of rough skin, which contains clathrate, in which the content of clathrate is 25% by weight or less of the total cosmetics.
剤、殺菌剤、油溶性色素剤及び香料からなる群から選択
された少なくとも1つの水難溶性成分をヒドロキシアル
キル化シクロデキストリンで包接した包接物を配合した
肌荒れ防止・改善性能に優れた粉末化粧料であって、そ
の包接物含有量が全化粧料中の50重量%以下である肌荒
れ防止・改善性能に優れた粉末化粧料。2. A hydroxyalkylated cyclodextrin includes at least one poorly water-soluble component selected from the group consisting of a polar oil, an ultraviolet absorber, an anti-inflammatory agent, an antiseptic, a bactericide, an oil-soluble coloring agent, and a fragrance. A powder cosmetic that is excellent in skin roughening prevention / improvement performance containing an inclusion material, and has an inclusion material content of 50% by weight or less of the total cosmetics. .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP27232589A JP2929108B2 (en) | 1988-10-28 | 1989-10-19 | Cosmetics and powder cosmetics |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63-272653 | 1988-10-28 | ||
JP27265388 | 1988-10-28 | ||
JP27232589A JP2929108B2 (en) | 1988-10-28 | 1989-10-19 | Cosmetics and powder cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02196709A JPH02196709A (en) | 1990-08-03 |
JP2929108B2 true JP2929108B2 (en) | 1999-08-03 |
Family
ID=26550146
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP27232589A Expired - Lifetime JP2929108B2 (en) | 1988-10-28 | 1989-10-19 | Cosmetics and powder cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2929108B2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0753396A (en) * | 1993-08-19 | 1995-02-28 | Ensuiko Sugar Refining Co Ltd | Cyclodextrin inclusion compound of taxol, its manufacturing method and use |
HU213200B (en) * | 1993-05-12 | 1997-03-28 | Chinoin Gyogyszer Es Vegyeszet | The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production |
JPH09208423A (en) * | 1995-11-30 | 1997-08-12 | Shiseido Co Ltd | Hydrating composition, cosmetics containing the same, and method for producing the same |
JP3940209B2 (en) * | 1996-11-14 | 2007-07-04 | 株式会社資生堂 | Solubilized cosmetics |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5470434A (en) * | 1977-11-16 | 1979-06-06 | Kobayashi Kose Co | Preparation of cosmetics |
DE3346123A1 (en) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF |
JPS61227517A (en) * | 1985-04-01 | 1986-10-09 | Lion Corp | Skin cosmetic |
JPH082773B2 (en) * | 1987-02-06 | 1996-01-17 | 花王株式会社 | Rose composition |
-
1989
- 1989-10-19 JP JP27232589A patent/JP2929108B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH02196709A (en) | 1990-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR0159271B1 (en) | Cosmetics containing inclusion product with hydroxyalkylated cyclodextrin and powder cosmetics thereof | |
EP0780115B1 (en) | Nanoparticles coated with a lamellar phase based on a silicone surfactant and compositions containing them | |
EP1016453B1 (en) | Nanoemulsion based on ethoxylated fatty ethers or ethoxylated fatty esters and uses thereof in the fields of cosmetics, dermatology and/or ophthalmology | |
CA2292797C (en) | Nanoemulsion with a base of fatty esters of glycerol and its cosmetic, dermatological and/or ophthalmological uses | |
EP1010415B1 (en) | Nanoemulsion based on fatty esters of oxyethylated or non- oxylated sorbitan and uses thereof in the fields of cosmetics, dermatology and/or ophthalmology | |
JP3455218B2 (en) | Cosmetic composition in the form of a water / oil / water ternary emulsion having a gelled external phase | |
JP3023078B2 (en) | Cosmetic and / or dermatological composition containing crosslinked poly (2-acrylamido-2-methylpropanesulfonic acid) and at least one active ingredient precursor | |
FR2788007A1 (en) | NANOEMULSION BASED ON BLOCK COPOLYMERS OF ETHYLENE OXIDE AND PROPYLENE OXIDE, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL AND / OR OPHTHALMOLOGICAL FIELDS | |
EP1013338A1 (en) | Nanoemulsion based on fatty esters of phosphoric acid and uses thereof in the fields of cosmetics, dermatology, pharmaceuticals and/or ophthalmology | |
FR2788449A1 (en) | NANOEMULSION BASED ON ALKYLETHER CITRATES, AND ITS USES IN THE COSMETIC, DERMATOLOGICAL, PHARMACEUTICAL AND / OR OPHTHALMOLOGICAL FIELDS | |
FR2536277A1 (en) | NOVEL ANTI-ACNE COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT | |
CN107108905A (en) | Water-soluble supramolecular complex | |
JPH1067639A (en) | Vitamin E-Vitamin C phosphoric acid diester / cyclodextrin clathrate and external skin preparation containing the clathrate | |
EP2598207A2 (en) | Surfactant-free oil-in-water type emulsion, process for preparation and uses thereof | |
JP3565975B2 (en) | External preparation for skin | |
CA2297560C (en) | Nanoemulsion based alkoxyle alkenyle succinates or alkoxyle glucose alkenyle succinates and it's use in cosmetics, dermatological, ophtalmological and/or pharmaceutical | |
CA2607718A1 (en) | Sunless tanning composition and methods for using | |
JP2929108B2 (en) | Cosmetics and powder cosmetics | |
JP2916689B2 (en) | Cosmetics | |
JP2941880B2 (en) | Emulsified cosmetic | |
JPH11139951A (en) | Cosmetic | |
JPS61227517A (en) | Skin cosmetic | |
JP3004675B2 (en) | External preparation for skin | |
JP2938120B2 (en) | External preparation for skin | |
JPH0358906A (en) | Cosmetics and powder cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090521 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100521 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100521 Year of fee payment: 11 |